Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis.

Area of Science:

• Oncology
• Molecular Genetics
• Cancer Biology

Background:

• Lipocalin-2 (Lcn2) is implicated in human tumor progression, particularly breast cancer, based on xenograft studies.
• Its precise role in mammary tumorigenesis and metastasis in vivo requires further investigation.

Purpose of the Study:

• To investigate the role of Lcn2 in mammary tumor development and lung metastasis using a genetically engineered mouse model.
• To elucidate the molecular mechanisms underlying Lcn2's function in breast cancer progression.

Main Methods:

• Crossed MMTV-PyMT transgenic mice with Lcn2-deficient mice (Lcn2-/-) on two different genetic backgrounds (129/Ola and C57BL/6).
• Monitored mammary tumor onset, progression, multiplicity, tumor burden, and lung metastasis over 20 weeks.
• Assessed matrix metalloproteinase-9 (MMP-9) activity in mammary tumors.

Main Results:

• Lcn2 deficiency delayed mammary tumor onset and significantly reduced tumor multiplicity and burden (2- to 3-fold) in MMTV-PyMT mice.
• Mammary tumors from Lcn2-/- mice exhibited reduced MMP-9 activity.
• Despite reduced tumor growth, Lcn2 deficiency did not significantly decrease lung metastasis incidence.

Conclusions:

• Lipocalin-2 is a potent inducer of mammary tumor growth in vivo.
• Lcn2 does not appear to be a significant promoter of lung metastasis in this breast cancer model.
• Findings highlight Lcn2's role in primary tumor development, distinct from its role in metastasis.